Traduction de «will be developed » (Néerlandais → Français) :

TERMINOLOGIE

Omschrijving: Het dragen van kleding van de andere sekse hoofdzakelijk om wille van de seksuele opwinding en om het beeld van iemand van de andere sekse op te roepen. Fetisjistisch transvestitisme wordt onderscheiden van transseksueel transvestitisme op grond van het duidelijk samengaan ervan met seksuele prikkeling en het sterke verlangen de kleding uit te trekken nadat het orgasme is opgetreden en de seksuele opwinding afneemt. Het kan voorkomen als een vroege fase in de ontwikkeling van transseksualiteit. | Neventerm: | transvestitistisch fetisjisme
Définition: Port de vêtements du sexe opposé, principalement dans le but d'obtenir une excitation sexuelle et de créer l'apparence d'une personne du sexe opposé. Le travestisme fétichiste se distingue du travestisme transsexuel par sa nette association avec une excitation sexuelle et par le besoin de se débarrasser des vêtements une fois l'orgasme atteint et l'excitation sexuelle retombée. Il peut survenir en tant que phase précoce du développement d'un transsexualisme. | Fétichisme avec travestisme

TRADUCTIONS EN CONTEXTE

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments.
This release contains forward-looking information that involves substantial risks and uncertainties regarding Prevenar 13, including its potential benefits; and the success of the AMC project for vaccines. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009, and in its reports on Form 10-Q and Form 8-K.

The primary objectives of the SOE-USE in the initial phase are to train these employees and to develop an infrastructure which will enable collaboration and data exchange between members.
The primary objectives of the SOE-USE in the initial phase are to train these employees and to develop an infrastructure which will enable collaboration and data exchange between members.

Additionally, a model will also be developed for a uniform working method for handling files, exchanging information and other tasks within the unit.
Additionally, a model will also be developed for a uniform working method for handling files, exchanging information and other tasks within the unit.

If standards are too strict, then early phase research becomes virtually impossible and the discovery and development of new medicines will be severely impeded.
If standards are too strict, then early phase research becomes virtually impossible and the discovery and development of new medicines will be severely impeded.

During the development of the FAMHP, due consideration will be given firstly to the role, functioning and composition of these commissions and consultation platforms and secondly to the representation of the FAMHP.
During the development of the FAMHP, due consideration will be given firstly to the role, functioning and composition of these commissions and consultation platforms and secondly to the representation of the FAMHP.

The Internal Audit & Quality service will be developed at a later date.
The Internal Audit & Quality service will be developed at a later date.

In addition to services of the Chief Executive Officer and the support services, threemain pillars will be developed:
In addition to services of the Chief Executive Officer and the support services, threemain pillars will be developed:

The Belgian Federal Agency for Medicines and Health Products, although it is still undergoing significant developments, will seize every opportunity to ensure higher levels of quality and improve its performance.
The Belgian Federal Agency for Medicines and Health Products, although it is still undergoing significant developments, will seize every opportunity to ensure higher levels of quality and improve its performance.